This is a news story about new findings indicating long-term benefits of cognitive-behavioral therapy for postpartum depression.
We can’t find any evidence that the findings this news story is based upon have been published yet, which is problematic–readers who want to learn more are left to fend to themselves. It appears, instead, that the findings were presented at the UK’s Royal Economic Society Annual conference in April, and perhaps will be published soon. But it’s far from clear where this story is getting its information from beyond a media briefing.
Now for what we do know: In 2008, a large controlled trial showed that a relatively simple form of cognitive-behavioral therapy for mothers diagnosed with depression was effective compared to the control group. In 2015, researchers checked in with the mothers to see how their children were doing. Now, in 2017, it appears, they’ve followed up to see how the mothers are doing–and it appears they’re doing well, still benefiting from the intervention. However, the data on this aren’t out yet.
This was a relatively low-intensity intervention (peers/community health workers delivering a modified CBT approach, called the Thinking Healthy Programme), used at a community level, designed to be used in a low-resource country.
For this reason, if this kind of program really does decrease maternal depression over the long-term, it could be very important for women all over the world. But news stories should not rush to report findings that haven’t been vetted yet.
We were glad that this short story mentioned the societal cost estimate for depression but still find it lacks any “cost” for the therapy under discussion.
For the clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, so the cost would be whatever it cost to add this training and time to their work. (Likely minimal.)
So, we think the story should have added a line or two acknowledging that it was a relatively affordable intervention where it was implemented–in Pakistan–but is likely to be of widely varying costs depending on where it’s used. In the U.S., for example, cognitive behavioral therapy typically requires 8-12 weeks of visits to a professional who charges between $180 and $250 per hour in the United States, according to Consumer Reports. Some of this might be covered by some insurance.
Here’s what the story said about benefits. The figures reported are in italics, sometimes in numbers and sometimes as percentages.
“The study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan. Within a year, more than half of the women in a control group (58%) were still depressed, whereas only a quarter of the mothers who had been treated with CBT reported depression.
“Returning to the women and their children seven years later, researchers found that the treated mothers were still significantly less likely to be depressed than the control group.”
The first paragraph of this passage was detailed and useful. But, considering that this story is all about the 7-year follow-up, there was not enough information on what was measured (in the second paragraph). What does “significantly less likely” mean, numerically? Had that been expressed in numbers or percentages, we’d have likely rated this Satisfactory.
The story does not make any statement on the risks or drawbacks of this intervention. However, given the relatively low-risk profile of cognitive-behavioral therapy, we’ll rate this N/A.
The story does provide some important details on the initial study:
The study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.
However, it doesn’t give us adequate information about the follow-up study on maternal outcomes. It states that it is based on research led by Sonia Bhalotra, of the Institute for Social and Economic Research, ISER, at the University of Essex, and that’s about it.
We could not find any publication of this presumably new research by Bhalotra. What we did find was a media briefing indicating that this research was recently presented at a conference–which indicates it should be considered preliminary until published. This point should have been stressed in the news story.
There was no disease mongering. We were also pleased that the story talked about multiple impacts on patients with this diagnosis, including their financial health.
Here is what the researcher said about the patients who responded to treatment: “Their mental health has improved, their financial situation and their empowerment over their lives, and undoubtedly the way they interact with their children.”
The story does not quote anyone independent of this study; this would have been very useful to include considering this is unpublished data (as far as we can tell).
The story mentions that people are often prescribed drugs for depression, and that CBT may be a better alternative.
The story didn’t address availability.
As explained in the original clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, making the treatment available in an area where it normally wouldn’t be.
But even in nations with more resources, spotty insurance coverage and lack of providers limit access to this type of care. The story should have at least touched up on the availability issue. This is an area an independent source likely could have given some context on.
The story established novelty in this way:
While studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.
We couldn’t find a news release per se, so we’ll rate this N/A. But we did find this media briefing. The story includes quotes not found in the briefing.
Systematic, Criteria-Driven
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like